Altimmune, Inc.
ALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $511,935 | $599,028 | $771,938 | $378,157 |
| - Cash | $36,926 | $135,117 | $111,097 | $190,301 |
| + Debt | $1,681 | $671 | $1,124 | $1,535 |
| Enterprise Value | $476,690 | $464,582 | $661,965 | $189,391 |
| Revenue | $20 | $426 | -$68 | $4,410 |
| % Growth | -95.3% | 726.5% | -101.5% | – |
| Gross Profit | $20 | $426 | -$68 | $4,410 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$94,812 | -$87,935 | -$84,409 | -$96,534 |
| % Margin | -474,060% | -20,642% | 124,130.9% | -2,189% |
| Net Income | -$95,059 | -$88,447 | -$84,713 | -$97,090 |
| % Margin | -475,295% | -20,762.2% | 124,577.9% | -2,201.6% |
| EPS Diluted | -1.34 | -1.66 | -1.81 | -2.35 |
| % Growth | 19.3% | 8.3% | 23% | – |
| Operating Cash Flow | -$79,848 | -$75,810 | -$62,586 | -$78,238 |
| Capital Expenditures | $0 | -$47 | -$126 | -$12,312 |
| Free Cash Flow | -$79,848 | -$75,857 | -$62,712 | -$90,550 |